# US 2025/0084042 A1 · Elagolix Sodium Compositions and Processes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084042 A1
- Document ID: US20250084042A1
- Status: Published application
- Kind: A1
- Application number: 18/953,666
- Filed: 2024-11-20
- Published: 2025-03-13
- Earliest claimed: 2018-07-23
- Assignees: AbbVie Inc.
- Applicants: AbbVie Inc.
- Inventors: Niharika Chauhan; Raimundo Ho; Albert Kruger; Samrat Mukherjee; Stephen T. Chau; Erika Crane; Alex Fabian; Sanjay Chemburkar; Travis Dunn
- Web page: https://patentgrep.com/patent/US20250084042A1

## CPC

- C07D 239/54: as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to compositions of elagolix sodium, and process and intermediates for the preparation thereof.

## Claims

### Claim 1

A composition of Compound (I) comprising,
Compound (I),
and
one or more impurities, wherein the composition comprises at least about 97 weight percent of Compound (I) and not more than about 3 weight percent of the one or more impurities.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the one or more impurities are selected from the group consisting of:

### Claim 3 (depends on 2)

The composition of claim 2, wherein Compound (I) is substantially amorphous.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the composition comprises at least 98 weight percent Compound (I) and not more than about 2 weight percent of the one or more impurities.

### Claim 5

A process for preparing a substantially pure composition of Compound (I) comprising:
using, as an intermediate in the process, Compound (II),

### Claim 6 (depends on 5)

The process of claim 5, further comprising, reacting Compound (IIa),
with salicylic acid to form Compound (II).

### Claim 7 (depends on 6)

The process of claim 6, further comprising, isolating Compound (II) to provide an isolated Compound (II); wherein the isolated Compound (II) is in crystalline form.

### Claim 8 (depends on 6)

The process of claim 6, further comprising,
reacting Compound (II) with a compound of formula (III),
where
R4 is C1-C8 alkyl;
X2 is Cl, Br, I, —OSO2CH3, —OSO2C6H4CH3 or —OSO2CF3; and
forming a compound of formula (IV),
where R6 is C1-C8 alkyl.

### Claim 9 (depends on 8)

The process of claim 8, further comprising,
treating a compound of formula (IV) with a sodium base to form Compound (I).

### Claim 10

A polymorphic form of a Compound (II):

### Claim 11 (depends on 10)

The polymorphic form of claim 10, wherein the polymorphic form is crystalline.

### Claim 12 (depends on 10)

The polymorphic form of claim 10, wherein the polymorphic form is a crystalline solid substantially free of amorphous Compound (II).

### Claim 13 (depends on 11)

The polymorphic form of claim 11, wherein the crystalline form is a solvated crystalline form.

### Claim 14 (depends on 13)

The polymorphic form of claim 13, wherein the solvated crystalline form is solvated with methanol.

### Claim 15 (depends on 14)

The polymorphic form of claim 14, wherein methanol is present in an amount from about 0.1 to 5.0 weight percent.

### Claim 16 (depends on 14)

The polymorphic form of claim 14, wherein the molar ratio of methanol to 3-[(2R)-2-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-6-methylpyrimidine-2,4(1H,3H)-dione is between about 0.1:1 and 1:1.

### Claim 17 (depends on 14)

The polymorphic form of claim 14, having an X-ray powder diffraction pattern comprising one or more peaks at ±0.2 of 7.0, 9.6, 10.7, 10.9, 11.4, 13.1, 13.5, 17.3, 17.5, and 18.2° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406.

### Claim 18 (depends on 17)

The polymorphic form of claim 17, having an X-ray powder diffraction pattern comprising peaks at ±0.2 of 7.0, 9.6, and 11.4° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 k.

### Claim 19 (depends on 13)

The polymorphic form of claim 13, wherein the solvated crystalline form is solvated with water.

### Claim 20 (depends on 19)

The polymorphic form of claim 19, wherein water is present in an amount from about 0.1 to 5.0 weight percent.

### Claim 21 (depends on 19)

The polymorphic form of claim 19, wherein the molar ratio of water to 3-[(2R)-2-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-6-methylpyrimidine-2,4(1H,3H)-dione is between about 0.3:1 and 0.6:1.

### Claim 22 (depends on 19)

The polymorphic form of claim 19, wherein the solvated crystalline form is additionally solvated with a solvent other than water.

### Claim 23 (depends on 22)

The polymorphic form of claim 22, wherein the solvent other than water is methanol.

### Claim 24 (depends on 23)

The polymorphic form of claim 23, wherein the molar ratio of methanol to water is about 1:0.5.

### Claim 25 (depends on 23)

The polymorphic form of claim 23, having an X-ray powder diffraction pattern comprising one or more peaks at 0.2 of 6.0, 8.1, 8.7, 9.5, 9.8, 10.6, 12.2, 12.5, 13.1, and 14.5° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406.

### Claim 26 (depends on 24)

The polymorphic form of claim 24, having an X-ray powder diffraction pattern comprising peaks at ±0.2 of 6.0, 9.8, and 12.5° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 K.

### Claim 27 (depends on 11)

The polymorphic form of claim 11, wherein the crystalline form is a desolvated and or dehydrated crystalline form.

### Claim 28 (depends on 27)

The polymorphic form of claim 27, having an X-ray powder diffraction pattern comprising one or more peaks at 0.2 of 6.1, 8.1, 8.7, 10.2, 10.4, 12.0, 13.1, 14.4, 16.6, and 17.4° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 K.

### Claim 29 (depends on 28)

The polymorphic form of claim 28, having an X-ray powder diffraction pattern comprising peaks at ±0.2 of 10.2, 10.4, and 12.0° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 K.

### Claim 30

A composition of Compound (I) comprising, Compound (I)
and
one or more impurities; wherein the composition comprises at least about 97 weight percent of Compound (I) and not more than about 3 weight percent of the one or more impurities, wherein the composition is prepared by a process comprising, using as an intermediate, Compound (II),

### Claim 31 (depends on 30)

The composition of claim 30, wherein the process further comprises reacting Compound (IIa),
with salicylic acid to form Compound (II).

### Claim 32 (depends on 31)

The composition of claim 31, wherein the process further comprises isolating Compound (II) to provide an isolated Compound (II).

### Claim 33 (depends on 30)

The composition of claim 30, wherein the one or more impurities are selected from the group consisting of

### Claim 34

A compound of formula (VI):
where
R11 is selected from the group consisting of hydrogen, M′, C1-C6 alkyl, C2-C4 alkenyl, C6-C10 aryl, 5-14 membered heteroaryl, J-(C6-C10 aryl), and J-(5-14 membered heteroaryl); wherein the C6-C10 aryl, 5-14 membered heteroaryl, J-(C6-C10 aryl), and J-(5-14 membered heteroaryl) may be optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, nitro, cyano, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C3-C11 cycloalkyl, 3-14 membered heterocyclyl, —ORa, —NRaRb, —NRaC(═O)Rc, —C(═O)Rc, —C(═O)OH, —C(═O)ORc, —C(═O)NaRb, —SO2R, and —SO2NRaRb;
Ra, and Rb are each independently selected from the group consisting of hydrogen, C1-C6 alkyl, C6-C10 aryl, and 5-14 membered heteroaryl;
Rc is selected from the group consisting of C1-C6 alkyl, C6-C10 aryl, and 5-14 membered heteroaryl;
J is C1-C2 alkylene;
M is selected from the group consisting of sodium, tetramethylguanidinium, 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepinium, 3,4,6,7,8,9-hexahydro-2H-pyrido[1,2-a]pyrimidinium, and 2-hydroxyethan-1-aminium; and
M′ is selected from the group consisting of sodium, lithium, and potassium.

### Claim 35 (depends on 34)

The compound of claim 34, which is:

### Claim 36 (depends on 35)

The compound of claim 35, wherein the compound of formula (VIa) is in crystalline form.

### Claim 37 (depends on 36)

The compound of claim 36, having an X-ray powder diffraction pattern comprising one or more peaks at ±0.2 of 6.1, 7.7, 8.9, 9.6, 10.7, 12.3, 14.7, 15.3, 16.6, 17.5, and 18.2° 20, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 K.

### Claim 38 (depends on 37)

The compound of claim 37, having an X-ray powder diffraction pattern comprising peaks at ±0.2 of 6.1, 7.7, and 18.2° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 K.

### Claim 39 (depends on 36)

The compound of claim 36, having an X-ray powder diffraction pattern comprising one or more peaks at ±0.2 of 5.9, 6.7, 8.5, 9.3, 10.7, 11.1, 15.3, 16.0, 17.4, and 17.8° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 K.

### Claim 40 (depends on 39)

The compound of claim 39, having an X-ray powder diffraction pattern comprising at ±0.2 of 5.9, 8.5, and 9.3° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 {acute over (Å)}.

### Claim 41 (depends on 36)

The compound of claim 36, wherein the solvated crystalline form is solvated with water, having an X-ray powder diffraction pattern comprising one or more peaks at ±0.2 of 6.0, 7.6, 8.9, 9.6, 10.7, 12.4, 14.8, 15.3, 16.6, 17.5, and 18.2° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406.

### Claim 42 (depends on 41)

The compound of claim 41, wherein the solvated crystalline form is solvated with water, having an X-ray powder diffraction pattern comprising peaks at ±0.2 of 6.0, 7.6, and 18.2° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 {acute over (Å)}.

### Claim 43 (depends on 36)

The compound of claim 36, wherein the solvated crystalline form is solvated with dimethyl sulfoxide, and having an X-ray powder diffraction pattern comprising one or more peaks at ±0.2 of 5.8, 7.3, 10.6, 12.1, 14.6, 15.0, 17.0, 17.5, 18.6, and 22.9° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 k.

### Claim 44 (depends on 43)

The compound of claim 43, wherein the solvated crystalline form is solvated with dimethyl sulfoxide, and having an X-ray powder diffraction pattern comprising peaks at ±0.2 of 5.8, 7.3, and 17.5° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 {acute over (Å)}.

### Claim 45 (depends on 36)

The compound of claim 36, wherein the solvated crystalline form is solvated with dichloromethane, and having an X-ray powder diffraction pattern comprising one or more peaks at ±0.2 of 5.9, 6.6, 8.4, 10.6, 11.7, 12.3, 14.8, 15.9, 17.6, 18.2, 18.9, and 20.7° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 k.

### Claim 46 (depends on 45)

The compound of claim 45, wherein the solvated crystalline form is solvated with dichloromethane, and having an X-ray powder diffraction pattern comprising one or more peaks at +0.2 of 11.7, 18.9, and 20.7° 2θ, when measured at about 25° C. with Cu—Kα1 radiation at 1.5406 {acute over (Å)}.

### Claim 47

A compound of formula (VII):
where
R10 is selected from the group consisting of sodium, lithium, potassium, hydrogen, C1-C6 alkyl, C2-C4 alkenyl, C6-C10 aryl, 5-14 membered heteroaryl, J-(C6-C10 aryl), and J-(5-14 membered heteroaryl); wherein the C6-C10 aryl, 5-14 membered heteroaryl, J-(C6-C10 aryl), and J-(5-14 membered heteroaryl) may be optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, nitro, cyano, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C3-C11 cycloalkyl, 3-14 membered heterocyclyl, —ORa, —NRaRb, —NRaC(═O)Rc, —C(═O)Rc, —C(═O)OH, —C(═O)ORc, —C(═O)NRaRb, —SO2Rc, and —SO2NRaRb;
Ra, and Rb are each independently selected from the group consisting of hydrogen and C1-C6 alkyl, C6-C10 aryl, and 5-14 membered heteroaryl;
Rc is selected from the group consisting of C1-C6 alkyl, C6-C10 aryl, and 5-14 membered heteroaryl;
J is C1-C2 alkylene;
L is selected from the group consisting of —SO—, —SO2—, and —P(O)OR12; and
R12 is selected from the group consisting of hydrogen and C1-C6 alkyl.

### Claim 48 (depends on 47)

The compound of claim 47, where L is —SO2—; and R10 is C1-C6 alkyl.

### Claim 49

A process for preparing a substantially pure composition of Compound (I), comprising:
using as an intermediate in the process, a compound of formula (VI);
where
R11 is selected from the group consisting of C1-C6 alkyl, C6 aryl, and J-(C6 aryl);
J is C1-C2 alkylene; and
M is selected from the group consisting of tetramethylguanidinium, 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepinium, 3,4,6,7,8,9-hexahydro-2H-pyrido[1,2-a]pyrimidinium, and 2-hydroxyethan-1-aminium; and
converting the compound of formula (VI) to Compound (I) by treatment with an acid and treatment with a first base.

### Claim 50 (depends on 49)

The process of claim 49, wherein converting the compound of formula (VI) to Compound (I) is at a temperature between about 10 to 35° C.;
wherein the acid has a pH between about 0.1 and 4.0; and
wherein the first base comprises a sodium cation.

### Claim 51

A composition of Compound (I), comprising:
Compound (I)
and
one or more impurities; wherein the composition comprises at least about 97 weight percent of Compound (I) and not more than about 3 weight percent of the one or more impurities; wherein the composition is prepared by a process comprising, using as an intermediate, Compound (VIa),

### Claim 52 (depends on 51)

The composition of claim 51, wherein the one or more impurities are selected from the group consisting of

### Claim 53

A composition of Compound (I) comprising,
Compound (I),
and
one or more impurities, wherein the composition comprises at least about 97 weight percent of Compound (I) and not more than about 3 weight percent of the one or, more impurities,
wherein the one or more impurities are selected from the group consisting of:
